开云app官网登录入口网页版-官方正版

#恩杂鲁胺#

2篇内容 | 2467人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2192947, encodeId=6f57219294ee8, content=<a href='/topic/show?id=2cfa10e777e8' target=_blank style='color:#2F92EE;'>#他拉唑帕利#</a> <a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a> <a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>, objectTitle=JCO：FDA批准他拉唑帕利联合恩杂鲁胺用于治疗HRR基因突变的晚期去势抵抗性前列腺癌, objectType=article, longId=816994, objectId=8b96816994b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240313/1710306304033_6145188.jpg, objectUrl=/article/show_article.do?id=8b96816994b0, replyNumber=0, likeNumber=77, createdTime=2024-03-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8b96816994b0, moduleTitle=JCO：FDA批准他拉唑帕利联合恩杂鲁胺用于治疗HRR基因突变的晚期去势抵抗性前列腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8b96816994b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2169307, encodeId=53b9216930e35, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a> <a href='/topic/show?id=60cb10e52478' target=_blank style='color:#2F92EE;'>#CRISPR - Cas9#</a>, objectTitle=Cancer Res：中山大学李永红/周芳坚/王军发现前列腺癌恩杂鲁胺耐药的潜在机理, objectType=article, longId=801252, objectId=e7ab801252dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=e7ab801252dd, replyNumber=0, likeNumber=84, createdTime=2023-11-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e7ab801252dd, moduleTitle=Cancer Res：中山大学李永红/周芳坚/王军发现前列腺癌恩杂鲁胺耐药的潜在机理, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e7ab801252dd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=886182, encodeId=6d19886182c9, content=与<a href='/topic/show?id=de489e856c6' target=_blank style='color:#2F92EE;'>#阿比特龙#</a>或<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>等雄激素信号抑制剂相比，<a href='/topic/show?id=02553650509' target=_blank style='color:#2F92EE;'>#卡巴他赛#</a>可显著改善转移性去势耐药性<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>患者的临床结果。卡巴他赛是第二代<a href='/topic/show?id=49ad10392134' target=_blank style='color:#2F92EE;'>#紫杉*类#</a>药物, objectTitle=NEJM：卡巴他赛用于治疗耐药性前列腺癌, objectType=article, longId=185296, objectId=6e62185296b2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201912/20191226184419664.jpg, objectUrl=/article/show_article.do?id=6e62185296b2, replyNumber=0, likeNumber=278, createdTime=2020-09-17, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e62185296b2, moduleTitle=NEJM：卡巴他赛用于治疗耐药性前列腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6e62185296b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月，还是相当不错吧, objectTitle=NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌, objectType=article, longId=195323, objectId=989d195323d7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202064/1591266757240_2051781.jpg, objectUrl=/article/show_article.do?id=989d195323d7, replyNumber=0, likeNumber=166, createdTime=2020-06-04, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989d195323d7, moduleTitle=NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=989d195323d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

恩杂鲁胺

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#他拉唑帕利# #恩杂鲁胺# #前列腺癌#

JCO：FDA批准他拉唑帕利联合恩杂鲁胺用于治疗HRR基因突变的晚期去势抵抗性前列腺癌

2024-03-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #恩杂鲁胺# #CRISPR - Cas9#

Cancer Res：中山大学李永红/周芳坚/王军发现前列腺癌恩杂鲁胺耐药的潜在机理

2023-11-18发表于上海

lovetcm (审核中...)

前往app查看评论内容

与#阿比特龙#或#恩杂鲁胺#等雄激素信号抑制剂相比，#卡巴他赛#可显著改善转移性去势耐药性#前列腺癌#患者的临床结果。卡巴他赛是第二代#紫杉*类#药物

NEJM：卡巴他赛用于治疗耐药性前列腺癌

2020-09-17

lovetcm (审核中...)

前往app查看评论内容

#恩杂鲁胺#延长去势耐受前列腺癌生存11个月，还是相当不错吧

NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌

2020-06-04

科室
- - 订阅+
  - 更多科室
工具
服务